BioSig Technologies, Inc. (BSGM)

Home

More information, better decisions

The PURE EP™ System sets a new standard in electrophysiology by providing essential intracardiac signals with high clinical value in all types of cardiac ablations.

Learn More About PURE EP™Learn More From the Users

More than 1,750 patient cases have been conducted using the PURE EP™ System by 73 physicians to date.

Incorporating Advanced Intracardiac Signal Information Into the Clinical Workflow

In this feature interview, EP Lab Digest speaks with Dr. Gallinghouse to discuss his use of and thoughts on the PURE EP™ System, including workflow integration, improved signal technology, and recent study results at Texas Cardiac Arrhythmia Institute

Press ReleaseDecember 14, 2021

BioSig Appoints Gray Fleming as Chief Commercial Officer

The seasoned electrophysiology sales executive joins the Company to expand the commercial footprint of its signal processing technology for arrhythmia care. Mr. Fleming brings to the Company over 20 years in the healthcare industry, including 17 years at Abbott Laboratories and St. Jude Medical.

Press ReleaseDecember 1, 2021

BioSig Initiates AI Development Program with Technion

BioSig announced that it entered into a feasibility study with The Technion Research & Development Foundation Ltd. Under the terms of the program, the ECG signals supplied by PURE EP™ will be analyzed in the context of developing AI-powered algorithms for atrial fibrillation ablation procedures.

Press ReleaseNovember 16, 2021

BioSig Adds To Its Clinical Footprint In Texas

BioSig announced that it is installing a PURE EP™ System for an evaluation at the HCA Healthcare-operated Medical City Heart Hospital in Dallas, TX. This is the Company’s 17th installation and its fifth in Texas, the state with some of the most extensive clinical programs focused on arrhythmia care in the country.

Press ReleaseNovember 10, 2021

Bioelectronic Medicine:
The Leading Edge of Healthcare

Bioelectronic medicine is a new, rapidly growing field of healthcare that explores how targeted electrical signals in the body can help to diagnose and treat a wide range of diseases, from diabetes to depression.
BioSig aims to play a vital role in the field of bioelectronic medicine, based on our unique enabling technology and core competency in signal processing. Our initial focus is on heart disease and the fast-growing electrophysiology device market.

What Is Bioelectronic Medicine?

The Need to Improve Arrhythmia Treatment

Heart Disease Is the
#1 Cause of Death

Arrhythmia, a common cardiac condition, causes the heart to beat too quickly, too slowly, or erratically. New signal processing technologies could play a key role in enhancing outcomes from one of the most important treatments for arrhythmia: catheter ablation.

Challenging, Costly Conditions

The health and economic impacts of arrythmia are immense. The most common arrhythmia, atrial fibrillation (AFib), affects 33 million people worldwide* – generating annual healthcare costs of $15,000 to $25,000 per patient*.

*Worldwide Epidemiology of Atrial Fibrillation in the journal Circulation, 2013; “Healthcare Costs Drop Sharply after Successful Ablation,” Marlene Busko, Medscape, May 4, 2016

Barriers to Treatment Efficacy

Treatment of AFib and ventricular tachycardia typically starts with drug therapy, which is often ineffective, particularly in the later stages of heart disease. Catheter ablation often fails, leading to costly repeat procedures.

The Importance of Signal Clarity

Clearer signal information may help physicians work faster and more accurately during catheter ablation. One of the main reasons for low ablation success rates is unreliable information – specifically, the inability to differentiate between the clean signal and lab noise.

PURE EP™: A Signal Processing Solution

By improving signal clarity, BioSig’s PURE EP™ System has the potential to deliver valuable advances in electrophysiology procedures. Clinical data acquired by the PURE EP™ System in a multi-center study at Texas Cardiac Arrhythmia Institute at St. David’s Medical Center, Mayo Clinic Jacksonville, and Massachusetts General Hospital was recently published in the Journal of Cardiovascular Electrophysiology. Study results showed 93% consensus across the blinded reviewers with a 75% overall improvement in intracardiac signal quality and confidence in interpreting PURE EP™ signals over conventional sources. Learn more from our physician users.

How Does Pure EP™ Work?

Key Scientific Publications

We’re proud of our high success rate for peer-reviewed publications in some of the leading medical journals. These publications provide early evidence that PURE EP™ could offer valuable improvements in signal clarity during electrophysiology procedures.

Browse Our Publications

Looking Beyond Arrhythmia

In 2017, BioSig signed a 10-year strategic collaboration with experts at Mayo Clinic to jointly develop our signal processing technology. These experts see the potential for our technology to help them electrically map the entire body, possibly leading to diagnosis and development of new therapies in other disease areas – for example, neurology and ophthalmology.

Learn About Our Partnerships

Creating Value for Investors

BioSig is a NASDAQ-traded company with a clear path to commercialization and growth, proven credentials for success, and a world-class leadership team. Check out our Investor Resources for financial and governance information, stock performance, SEC filings, and other materials.

See Investor Resources